When analyzing levels of known markers for neuronal damage in NDEs, levels of high mobility group box 1 (HMGB1), neurofilament light (NfL), p-T181-tau, and amyloid beta (Aβ) were compared across the control group (HIV-negative NPN), HIV-positive NPN, and combined HIV-positive asymptomatic neurological impairment (ANI) and mild neurocognitive disorder (MND) 69. The gene discussed is MAPT; the disease is mild neurocognitive disorder.